Navigation Links
BD Statement Regarding Impact of Japan Earthquake
Date:3/15/2011

FRANKLIN LAKES, N.J., March 15, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) has operations in Japan led by its Nippon Becton Dickinson headquarters office in Tokyo, and a manufacturing facility and distribution center in Fukushima prefecture.  The Company today confirmed that all of its employees in Japan are safe and that its office in Tokyo is undamaged and functional. BD's manufacturing plant and distribution center in Fukushima are temporarily closed while the Company assesses damage, which does not appear to be extensive.  BD is also in the process of evaluating access to utilities and transportation, which have been impacted throughout Japan due to the earthquake and tsunami. BD sources certain component parts and finished products from third-party suppliers in Japan, and currently believes that inventories of these items will be sufficient to meet global demand until supply chain interruptions are resolved.

Revenues in Japan represented approximately 5 percent of BD's fiscal year 2010 revenues.  Revenues from products manufactured in Japan (BD Hypak™ Prefillable Syringes and prepared plated media) represented approximately 1 percent of BD's fiscal year 2010 revenues.

BD is actively engaged with many disaster relief organizations in supporting the humanitarian aid effort.

About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com. Contact:Colleen T. White, Corporate Communications – 201-847-5369Zachary A. Nagle, Investor Relations – 201-847-5453
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Assured Pharmacy Completes Audit of 2008-2009 Financial Statements
2. Statement: PILMA Applauds Senate Passage of Patent Reform
3. The FDA Releases a Public Health Statement on Metal-on-Metal Hip Implants
4. Nephros Rights Offering Registration Statement Declared Effective
5. Vanda Pharmaceuticals Files Shelf Registration Statement
6. Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA
7. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
8. Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
9. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
10. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
11. Cannabis Science Files Preliminary 14c Information Statement, the Action is to Create a New Class of Common Stock and Issue Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... , April 19, 2017 Global Prostate ... report on the prostate cancer therapeutics market analyzes ... market. Increasing prevalence of prostate cancer, launch of ... the development of new drugs & therapeutic biological ... drug due to lesser side effects are some ...
Breaking Medicine Technology:
(Date:4/21/2017)... West Palm Beach, FL (PRWEB) , ... April 21, 2017 , ... The staff at ... FACS , will be taking part in the 2017 London Marathon. Set to take place ... variety of charitable organizations. This year, Dr. Schwartz will run as part of team EMPOWER, ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... for adolescents and young adults, has kicked off its 4th annual Forum for ... This year’s theme is “Attachment Informed Therapy for Mental Health and Addiction.” ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its new ... the full potential of specialty and orphan brands can only be achieved when the ... “The Unifying Effect is at the heart of a true partnership between our agency ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... named Agency of Record (AOR) for Theravent, Inc. , the makers of ... parent company, Foundation Consumer Healthcare, is now working to expand distribution in anticipation ...
(Date:4/21/2017)... ... 21, 2017 , ... The American Medical Student Association (AMSA) ... Recovery Education, from April 24 to April 28, 2017, dedicated to increasing awareness ... The mission of AWARE is to instill a compassionate, total health approach to ...
Breaking Medicine News(10 mins):